Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
about
Interventions for treating bisphosphonate-related osteonecrosis of the jaw (BRONJ)Bisphosphonates for preventing and treating osteoporosis in menChinese herbal medicines for treating osteoporosisSelective estrogen receptor modulators for preventing and treating postmenopausal osteoporosisExercise for improving outcomes after osteoporotic vertebral fractureDenosumab for the treatment and prevention of postmenopausal osteoporosisHuman parathyroid hormone for the treatment of osteoporosis in post-menopausal womenBisphosphonates for osteoarthritisPharmacologic interventions for preventing and treating periprosthetic osteoporosis following total hip arthroplastyBisphosphonates for osteoporosis in primary biliary cirrhosisHormone replacement for osteoporosis in women with primary biliary cirrhosisIntravenous zoledronate for postmenopausal osteoporosisWhole body vibration for preventing and treating osteoporosisVitamin K for the prevention and treatment of osteoporosis in post-menopausal womenOnce-yearly zoledronic acid in hip fracture preventionSurgical prevention of femoral neck fractures in elderly osteoporotic patients. A literature reviewAlendronate prevents glucocorticoid-induced osteoporosis in patients with rheumatic diseasesThe carcinogenicity of alendronate in patients with osteoporosis: evidence from cohort studiesCarpal Tunnel Syndrome Associated with Oral Bisphosphonates. A Population-Based Cohort StudyFalls and Fall-Related Injuries among Community-Dwelling Adults in the United StatesEffectiveness of a minimal resource fracture liaison serviceMind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures.Protocol for the Osteoporosis Choice trial. A pilot randomized trial of a decision aid in primary care practiceEfficacy and safety of medical therapy for low bone mineral density in patients with Crohn disease: A systematic review with network meta-analysis.Current and Future Incidence and Costs of Osteoporosis-Related Fractures in The Netherlands: Combining Claims Data with BMD MeasurementsBisphosphonates and atrial fibrillation: Bayesian meta-analyses of randomized controlled trials and observational studies.A scoping review of strategies for the prevention of hip fracture in elderly nursing home residents.Long-Term Alendronate Use Not without Consequences?The correlation of osteoporosis to clinical features: a study of 4382 female cases of a hospital cohort with musculoskeletal symptoms in southwest ChinaWhat are the beliefs, attitudes and practices of front-line staff in long-term care (LTC) facilities related to osteoporosis awareness, management and fracture prevention?Fracture Preventing Effects of Maxmarvil® Tablets (Alendronate 5 mg + Calcitriol 0.5 µg) in Patients with OsteoporosisSeven years' experience with alendronate in postmenopausal Japanese women with osteoporosis.Implications of expanding indications for drug treatment to prevent fracture in older men in United States: cross sectional and longitudinal analysis of prospective cohort study.Is bisphosphonate therapy for benign bone disease associated with impaired dental healing? A case-controlled studyOsteoporosis prevention, screening, and treatment: a review.Additive effects of nutritional supplementation, together with bisphosphonates, on bone mineral density after hip fracture: a 12-month randomized controlled study.Application of the National Osteoporosis Foundation Guidelines to postmenopausal women and men: the Framingham Osteoporosis StudyLow acceptance of treatment in the elderly for the secondary prevention of osteoporotic fracture in the acute rehabilitation settingOral bisphosphonates and risk of cancer of oesophagus, stomach, and colorectum: case-control analysis within a UK primary care cohort.Orthopaedic surgeons' strategies in pharmacological treatment of fragility fractures.
P2860
Q24186105-4C001269-BAFE-49DF-9231-6B6DA7F9C3CBQ24197612-BC5B0C2D-C14E-456A-8DEA-2937EF01D030Q24198040-64E2E1CE-FF48-4CD4-A8BA-AC3F6CB98B93Q24200755-203F19E7-787B-497C-9505-71CE532C5C00Q24201831-3B14CEFA-917F-4C57-9934-AB830EF5622AQ24201859-853D55D3-85B4-4F77-AD6A-B371F9723A29Q24202763-69839941-65BF-4DB8-93E0-8653C503AA7AQ24202794-F2E88EFE-2751-432B-9E64-075B67B6B294Q24202797-37E40F29-A1A6-43A0-8A34-1D927FFBC7D1Q24234283-3035702E-9C8D-418A-8DE4-96147F3D09ACQ24234575-8FD3DA1B-4618-49EF-9DCA-54E84E7A93CCQ24239823-AAC8DAD0-ED5F-4478-B403-A06C5A75A00DQ24239866-6B702D8F-8F1A-40D2-BD93-B804B335E496Q24239937-EB3FB28D-313A-4C02-82C7-C80E68AA6430Q24657667-BC964A31-888D-4DF7-B7B2-7DD24036A65DQ26744057-5AF44B51-F56D-4510-8799-C8AB0E6F458FQ27314920-2ADB5295-FBC0-409A-BA1F-17FCFA125373Q28087279-69D233E1-752A-4BEF-977E-F1F1AE0EC431Q28384121-BFEFC32C-E8BD-45C9-A2C8-08B38DD5152CQ28389707-0CECAB42-B43F-4393-92EC-A7225F071F92Q28391373-B3CD3E7D-6E96-4302-9A5D-B6659959CF3EQ30236007-F0BE1C1C-CA5D-47E5-9B24-C90AD76BDAE1Q30492459-0C935054-71CE-4D40-AB19-1ADF9A95472EQ30843177-880E2040-526E-4793-ABA8-EC5F55A5BD30Q31035996-F1A5F9AC-8BF3-4DC3-990C-D12D61C1C3EFQ33505798-F3F8D53C-9E59-48E0-8FE0-818EB1F60464Q33538008-0315B5F5-DFC7-402C-9E2C-24E9A06ADE41Q33633821-2E278E84-CF02-422F-80E7-B512ADCC4C7EQ33659574-DB167193-68CB-4066-8CC4-ED05181756A1Q33712519-D5D7D312-ABB2-4CFA-A692-6F112917C7A7Q33804860-7C0562EF-9AEF-47B6-BEDA-5DCEFD4EAF38Q33817802-B6CA0719-58CD-4262-9A8C-FC946465F2BAQ33842226-43601545-36E1-4C2A-97B4-7DA37FD902FEQ33866456-9C8E6AC8-B84F-4F0E-B02D-E887015F9A0DQ33870810-D0A66FF0-8592-4AC0-B1BB-118F74344B75Q33890224-3C1737AF-AFF2-49D0-AB6D-698283F31615Q33929951-C30A4A38-7517-44C6-9497-3AB81A0F8805Q34055595-27593563-CEAA-44FB-A06F-904B3B098040Q34104102-33359E05-2FBD-4656-936E-E9F5E458F857Q34230286-B42AD139-A149-4D62-8B7D-C72BBE306A31
P2860
Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women
description
2008 nî lūn-bûn
@nan
2008 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2008 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2008年の論文
@ja
2008年論文
@yue
2008年論文
@zh-hant
2008年論文
@zh-hk
2008年論文
@zh-mo
2008年論文
@zh-tw
2008年论文
@wuu
name
Alendronate for the primary an ...... ctures in postmenopausal women
@ast
Alendronate for the primary an ...... ctures in postmenopausal women
@en
Alendronate for the primary an ...... ctures in postmenopausal women
@en-gb
Alendronate for the primary an ...... ctures in postmenopausal women
@nl
type
label
Alendronate for the primary an ...... ctures in postmenopausal women
@ast
Alendronate for the primary an ...... ctures in postmenopausal women
@en
Alendronate for the primary an ...... ctures in postmenopausal women
@en-gb
Alendronate for the primary an ...... ctures in postmenopausal women
@nl
prefLabel
Alendronate for the primary an ...... ctures in postmenopausal women
@ast
Alendronate for the primary an ...... ctures in postmenopausal women
@en
Alendronate for the primary an ...... ctures in postmenopausal women
@en-gb
Alendronate for the primary an ...... ctures in postmenopausal women
@nl
P2093
P2860
P50
P3181
P1476
Alendronate for the primary an ...... ctures in postmenopausal women
@en
P2093
Ann Cranney
George A Wells
Joan Peterson
Michel Boucher
P2860
P3181
P356
10.1002/14651858.CD001155.PUB2
P577
2008-01-23T00:00:00Z